Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study

Area of Science:

• Cardiology
• Immunology
• Medical Technology

Background:

• Severe heart failure due to dilated cardiomyopathy significantly impacts cardiac function.
• Immunoadsorption (IA) has shown promise in improving hemodynamics in these patients.
• Previous studies suggest repeated IA courses offer prolonged hemodynamic benefits.

Purpose of the Study:

• To compare the efficacy of a single course of IA versus repeated monthly courses in patients with severe heart failure.
• To evaluate the impact of IA on left ventricular ejection fraction (LVEF) and hemodynamic parameters.
• To determine the duration of beneficial effects from a single IA course.

Main Methods:

• A randomized study involving 22 patients with severe heart failure (LVEF <35%) due to dilated cardiomyopathy.
• Group 1 (11 patients) received four IA courses monthly; Group 2 (11 patients) received one IA course.
• Left ventricular function and hemodynamics were assessed at 3 and 6 months post-treatment.

Main Results:

• Both single and repeated IA courses significantly improved LVEF after 6 months (P < .01 vs baseline).
• Cardiac index also showed significant improvement in both groups after 6 months (P < .01 vs baseline).
• No significant differences in LVEF or hemodynamic parameters were observed between the groups at 3 or 6 months.

Conclusions:

• A single course of IA treatment can significantly improve left ventricular function for at least six months.
• The benefits of a single IA course are comparable to those achieved with repeated monthly IA treatments.
• IA therapy offers a potentially effective and less intensive treatment option for severe heart failure.